8-K: NeuroPace Q2 2025 Revenue Up, Guidance Raised

NeuroPace reported record Q2 2025 revenue of $23.5 million and increased its full-year 2025 revenue guidance to $94-$98 million, driven by RNS System sales.

Summary

• Reported record quarterly revenue of $23.5 million in Q2 2025, representing 22% year-over-year growth compared to $19.3 million in Q2 2024.
• RNS System revenue grew 21% year-over-year for the first half of 2025 and 16% for the second quarter of 2025.
• Achieved a strong gross margin of 77.1% in Q2 2025, up from 73.4% in Q2 2024 and 77.0% in Q1 2025.
• Net loss for Q2 2025 was $8.7 million, compared to $7.5 million in Q2 2024.
• Total operating expenses increased to $25.0 million in Q2 2025 from $20.4 million in Q2 2024, largely due to $1.9 million in one-time personnel expenses.
• Cash, cash equivalents, and short-term investments stood at $62.1 million as of June 30, 2025.
• Refinanced existing debt into a new $75 million credit facility with MidCap Financial at favorable terms.
• Increased full-year 2025 total revenue guidance to between $94 million and $98 million, up from previous guidance of $93 million and $97 million.
• Increased full-year 2025 gross margin guidance to between 75% and 76%, up from previous guidance of 73% and 75%.
• Preliminary one-year data from the NAUTILUS study for IGE showed a statistically significant safety profile but did not meet the primary effectiveness endpoint; however, secondary endpoints demonstrated 79% median GTC seizure reduction at 12 months.
• CMS maintained the current MS-DRG assignment (MS-DRG 023) for RNS System procedures in its FY 2026 IPPS final rule, preserving reimbursement stability.

Sentiment

Score: 8

Explanation: The company reported strong financial performance with record revenue and improved gross margin, coupled with increased full-year guidance. Strategic progress in clinical trials (NAUTILUS secondary endpoints) and regulatory stability (CMS ruling) are significant positives, despite a wider net loss primarily due to one-time expenses and the NAUTILUS primary effectiveness endpoint not being met. The debt refinancing is also a positive financial move.

Positives

• Record quarterly revenue of $23.5 million in Q2 2025, a 22% year-over-year increase.
• Strong gross margin of 77.1% in Q2 2025, driven by manufacturing efficiencies and positive product mix.
• Increased full-year 2025 revenue guidance to $94 million $98 million, reflecting continued growth.
• Increased full-year 2025 gross margin guidance to 75% 76%, indicating improved profitability expectations.
• Successful refinancing of existing debt into a new $75 million credit facility at favorable terms.
• NAUTILUS study demonstrated a statistically significant safety profile and clinically meaningful improvement across multiple prespecified secondary effectiveness endpoints, including 79% median GTC seizure reduction at 12 months for IGE.
• CMS maintained MS-DRG 023 assignment for RNS System procedures, ensuring reimbursement stability for Medicare patients.
• Achieved record highs in both active accounts and prescribers, indicating growing adoption of RNS therapy.

Negatives

• Net loss widened to $8.7 million in Q2 2025 from $7.5 million in Q2 2024.
• Total operating expenses increased to $25.0 million, partly due to $1.9 million in one-time personnel expenses (severance, recruiting, executive transition).
• The NAUTILUS study did not reach statistical significance on the primary effectiveness endpoint for IGE.

Risks

• Actual operating results may differ significantly from any guidance provided.
• Uncertainties related to market acceptance and adoption of the RNS System.
• Operating expenses could be higher than anticipated, leading to faster depletion of cash resources.
• Gross margin may be lower than forecast.
• Risks related to the pricing of the RNS System and availability of adequate reimbursement for procedures and ongoing patient care.
• Risks related to regulatory compliance and expectations for regulatory submissions and approvals to expand the market for the RNS System, including risks related to the NAUTILUS clinical trial.
• Risks related to product development, including the development of AI-powered software and the next-generation device platform.
• Reliance on contractors and other third parties, including single-source suppliers and vendors.

Future Outlook

NeuroPace anticipates submitting NAUTILUS study data to the FDA in the second half of 2025 for potential indication expansion of the RNS System for Idiopathic Generalized Epilepsy (IGE). The company is also advancing its pediatric PMA supplement programs and AI software development programs, aiming to address unmet patient needs and set new standards of care for drug-resistant epilepsy. Management expects continued business momentum, driving increased access and adoption of RNS therapy, and supporting operating leverage for sustained long-term growth.

Management Comments

• "We are pleased with the continued momentum in our business through the second quarter of 2025, as we made significant progress across a number of key initiatives to position NeuroPace for sustained long-term growth."
• "We are advancing our strategy, driving increased access to and adoption of RNS therapy and supporting operating leverage as we scale."
• "We also made important clinical and regulatory and research and development progress in the quarter, including advancing our NAUTILUS and the pediatric PMA supplement programs and advancing our AI software development programs. These efforts reflect our leadership in the field, commitment to addressing unmet patient needs, and setting the standard of care for drug-resistant epilepsy."

Industry Context

NeuroPace operates in the specialized medical device sector, focusing on neuromodulation for drug-resistant epilepsy. The RNS System, a brain-responsive platform, positions the company at the forefront of personalized epilepsy treatment. The pursuit of IGE indication expansion and AI software development aligns with broader industry trends towards precision medicine and advanced neurotechnology. The favorable CMS reimbursement decision is crucial for maintaining market access and stability within the U.S. healthcare system, a key factor for medical device companies.

Comparison to Industry Standards

• The NAUTILUS study's 79% median GTC seizure reduction at 12 months for IGE significantly exceeded the 44% reduction observed in the company's pivotal trial for focal epilepsy, suggesting a strong efficacy profile for this new indication compared to previously approved uses.
• The gross margin of 77.1% is robust for a medical device company, indicating strong manufacturing efficiencies and a favorable product mix, potentially outperforming many industry peers.
• The refinancing of existing debt into a new $75 million credit facility at favorable terms demonstrates the company's financial health and ability to secure capital on competitive terms, which is a positive indicator compared to companies facing higher borrowing costs or limited access to credit.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, increased guidance, improved gross margin, and strategic progress, potentially leading to increased share value.
• Patients: Potential for expanded access to RNS therapy for a broader population (IGE, pediatric) and improved outcomes through advanced technology.
• Healthcare Providers/Prescribers: Increased adoption and record highs in active accounts and prescribers indicate growing acceptance and use of the RNS System.
• Employees: One-time personnel expenses including severance and recruiting suggest some workforce adjustments, but overall growth implies stability for many.
• Creditors: Debt refinancing at favorable terms with MidCap Financial indicates a healthy relationship and manageable debt profile.

Next Steps

• Submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025.
• Continue constructive engagement with CMS to ensure future policies reflect the full value of RNS therapy.
• Advance pediatric PMA supplement programs.
• Advance AI software development programs.

Key Dates

Recommendation

The company delivered strong Q2 2025 results, exceeding expectations by raising full-year revenue and gross margin guidance. The significant growth in RNS System revenue, coupled with a robust gross margin, indicates strong operational efficiency and market demand. While the NAUTILUS study's primary effectiveness endpoint for IGE was not met, the statistically significant safety profile and clinically meaningful improvement in secondary effectiveness endpoints (79% median GTC seizure reduction) are highly promising for future indication expansion and patient outcomes. The favorable CMS reimbursement decision provides critical stability for market access. The debt refinancing at favorable terms further strengthens the balance sheet. Despite a wider net loss, the underlying business momentum, strategic advancements, and positive outlook suggest significant upside potential for investors.

Keywords

NeuroPace, NPCE, Epilepsy, RNS System, Medical Device, Neuromodulation, Brain-responsive, Seizure Reduction, NAUTILUS Study, IGE, Drug-resistant Epilepsy, Financial Results, Revenue Guidance, Gross Margin, SEC Filing, 8-K, Q2 2025, Earnings